Zoetis (ZTS)
I think it deserves a thread.
  • "Zoetis Inc. has fallen 71% from its 2021 peak, now trading at 2017 levels, as pricing power eroded and pet medicine volumes declined.
  • Despite near-term headwinds, Zoetis maintains industry-leading margins and is positioned to weather price wars better than rivals due to its product mix and scale.
  • Patent expiries for Apoquel and Simparica in 2030/2032 are key risks, but a robust pipeline of 12 candidates could offset revenue losses if half succeed."
7
20 comments
Leon K
7
Zoetis (ZTS)
Invest & Retire Community
skool.com/invest-retire-community-1699
Follow my weekly options income trade ideas and blue-chip stock research for retirement cash flow and long-term growth. New ideas every week.
Leaderboard (30-day)
Powered by